spacer
home > ict > spring 2020 > uk data protection in post-marketing pharmacovigilance
PUBLICATIONS
International Clinical Trials

UK Data Protection in Post-Marketing Pharmacovigilance



In the UK, the Data Protection Act (DPA) 2018 governs the processing of personal data and implements the European GDPR: Regulation (EU) 679/20161. The GDPR came into force on 25 May 2018 and replaced the EU Directive 95/46/EC (the Data Protection Directive). Even though the UK has left the EU, the DPA brings GDPR requirements into UK law and extends it to cover legal areas for which the EU does not have oversight. It will remain in force after the UK leaves the EU.

In terms of scope, we need to be aware that the GDPR applies both in and outside of the UK and EU. Health data and other sensitive data cannot be processed without informed consent, unlessan exception applies, but when it comes to fulfilling pharmacovigilance (PV) obligations, processing the data is necessary as stated in Article 9.

In PV, there are two types of data that are subject to regulation:

1. Personal data received from the collection of reports (e.g., adverse event reports by email notifications)

2. Collected data that no longer contain personal data (e.g., subject identifiers replaced in order to pseudonymise the data)

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Avile Grey is pharmacovigilance professional with an MSc in Pharmacovigilance at the University of Hertfordshire, UK. She has been an active member of the PIPA Training Working Party since 2013.

emu0420@gmail.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

KITE’S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) RECEIVES POSITIVE CHMP OPINION IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA

Stockley Park, UK – 22 July 2022 – Kite, a Gilead Company, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (ALL). If approved, brexucabtagene autoleucel will be the first and only CAR T-cell therapy for this population of patients who have limited treatment options. Half of adults with ALL will relapse, and median overall survival (OS) for this group is only approximately eight months with current standard-of-care treatments.[1],[2]
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement